Department of Cancer Biology, University of Pennsylvania, Philadelphia, United States; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, United States
Clementina Mesaros
Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, United States
Luke Izzo
Department of Cancer Biology, University of Pennsylvania, Philadelphia, United States; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, United States
Hayley Affronti
Department of Cancer Biology, University of Pennsylvania, Philadelphia, United States; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, United States
Department of Cancer Biology, University of Pennsylvania, Philadelphia, United States; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, United States
Bethany E Schaffer
Meyer Cancer Center and Department of Pharmacology, Weill Cornell Medicine, New York, United States
Tiffany Tsang
Department of Cancer Biology, University of Pennsylvania, Philadelphia, United States; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, United States
Kathryn Sun
Pancreatic Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
Sophie Trefely
Department of Cancer Biology, University of Pennsylvania, Philadelphia, United States; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, United States; Center for Metabolic Disease Research, Department of Microbiology and Immunology, Lewis Katz School of Medicine, Temple University, Philadelphia, United States
Salisa Kruijning
Department of Cancer Biology, University of Pennsylvania, Philadelphia, United States; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, United States
John Blenis
Meyer Cancer Center and Department of Pharmacology, Weill Cornell Medicine, New York, United States
Ian A Blair
Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, United States
Department of Cancer Biology, University of Pennsylvania, Philadelphia, United States; Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, United States
Tumors frequently exhibit aberrant glycosylation, which can impact cancer progression and therapeutic responses. The hexosamine biosynthesis pathway (HBP) produces uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), a major substrate for glycosylation in the cell. Prior studies have identified the HBP as a promising therapeutic target in pancreatic ductal adenocarcinoma (PDA). The HBP requires both glucose and glutamine for its initiation. The PDA tumor microenvironment is nutrient poor, however, prompting us to investigate how nutrient limitation impacts hexosamine synthesis. Here, we identify that glutamine limitation in PDA cells suppresses de novo hexosamine synthesis but results in increased free GlcNAc abundance. GlcNAc salvage via N-acetylglucosamine kinase (NAGK) is engaged to feed UDP-GlcNAc pools. NAGK expression is elevated in human PDA, and NAGK deletion from PDA cells impairs tumor growth in mice. Together, these data identify an important role for NAGK-dependent hexosamine salvage in supporting PDA tumor growth.